NKX6.1 Antibody [N24F3] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Lane 1: INS-1

Usage Information

Dilution
WB1:1000 IP1:50 IHC1:3200 IF1:400 FCM1:200

Application
WB, IP, IHC, IF, FCM

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
44, 46

Positive Control	Mouse pancreas; Human pancreas; β-TC-6 cells; NIT-1 cells; INS-1 cells
Negative Control	mIMCD3 cells

Datasheet & SDS

Biological Description

Specificity
NKX6.1 Antibody [N24F3] detects endogenous levels of total NKX6.1 protein.

Clone
N24F3

Synonym(s)
Homeobox protein Nkx-6.1; Homeobox protein NK-6 homolog A; NKX6-1; NKX6A

Background
NKX6.1 is a homeodomain-containing transcription factor essential for pancreatic β-cell development and identity. It contains a conserved 60-amino-acid homeodomain, consisting of three α-helices, with helix III specifically recognizing TAAT-core motifs flanked by distinct nucleotides in target gene promoters. NKX6.1 also features an N-terminal transcriptional repression domain and a C-terminal β-interaction domain (BID), which together enable activation, autoregulation, and interactions with cofactors such as Pdx1, Pax4, and MafA. Expressed in multipotent pancreatic progenitors, NKX6.1 drives endocrine lineage commitment by directly repressing acinar fate genes such as Ptf1a and activating β-cell-specific transcription factors (e.g., Hnf1α, Mnx1, Rfx6) as well as metabolic genes (such as Glut2, G6pc2, Slc30a8, and Ero1lb). This is accomplished through chromatin looping and recruitment of coactivators. NKX6.1 maintains mature β-cell function by supporting glucose-stimulated insulin secretion (GSIS), potentiated by VGF/TLQP-21 and Nr4a1/Nr4a3-mediated proliferation, while concurrently suppressing glucagon (Gcg) expression and epithelial-mesenchymal transition to prevent dedifferentiation. In Notch-repressed trunk progenitors, NKX6.1 is critical for sustaining β-cell mass and identity after birth. Loss of NKX6.1 function leads to β-to-α/δ cell transdifferentiation, hyperglycemia, and diabetes mellitus. Conversely, NKX6.1 overexpression can enhance β-cell proliferation and GSIS, but may also increase the risk of tumorigenesis through dysregulation of Nr4a and c-Fos signaling pathways.

Background

NKX6.1 is a homeodomain-containing transcription factor essential for pancreatic β-cell development and identity. It contains a conserved 60-amino-acid homeodomain, consisting of three α-helices, with helix III specifically recognizing TAAT-core motifs flanked by distinct nucleotides in target gene promoters. NKX6.1 also features an N-terminal transcriptional repression domain and a C-terminal β-interaction domain (BID), which together enable activation, autoregulation, and interactions with cofactors such as Pdx1, Pax4, and MafA. Expressed in multipotent pancreatic progenitors, NKX6.1 drives endocrine lineage commitment by directly repressing acinar fate genes such as Ptf1a and activating β-cell-specific transcription factors (e.g., Hnf1α, Mnx1, Rfx6) as well as metabolic genes (such as Glut2, G6pc2, Slc30a8, and Ero1lb). This is accomplished through chromatin looping and recruitment of coactivators. NKX6.1 maintains mature β-cell function by supporting glucose-stimulated insulin secretion (GSIS), potentiated by VGF/TLQP-21 and Nr4a1/Nr4a3-mediated proliferation, while concurrently suppressing glucagon (Gcg) expression and epithelial-mesenchymal transition to prevent dedifferentiation. In Notch-repressed trunk progenitors, NKX6.1 is critical for sustaining β-cell mass and identity after birth. Loss of NKX6.1 function leads to β-to-α/δ cell transdifferentiation, hyperglycemia, and diabetes mellitus. Conversely, NKX6.1 overexpression can enhance β-cell proliferation and GSIS, but may also increase the risk of tumorigenesis through dysregulation of Nr4a and c-Fos signaling pathways.

References
https://pubmed.ncbi.nlm.nih.gov/33121533/ https://pubmed.ncbi.nlm.nih.gov/23382704/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%